Jul 1, 2025 Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering Learn More
Jun 26, 2025 Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement Learn More
Jun 24, 2025 Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC) Learn More